TY - JOUR
T1 - Assessment of immunovirological features in HIV related non-Hodgkin lymphoma patients and their impact on outcome
AU - Tedeschi, Rosamaria
AU - Bortolin, Maria Teresa
AU - Bidoli, Ettore
AU - Zanussi, Stefania
AU - Pratesi, Chiara
AU - Vaccher, Emanuela
AU - Tirelli, Umberto
AU - De Paoli, Paolo
PY - 2012/4
Y1 - 2012/4
N2 - Background: Despite the era of highly active antiretroviral therapy, non-Hodgkin lymphoma (NHL) remains one of the main causes of death in HIV-infected patients, with a wide variation on the outcome. Objectives: We investigated immunological status and EBV, HHV8, HIV viral load in a group of HIV-infected patients at diagnosis of NHL to evaluate their prognostic significance. Study design: Eighty-one consecutive HIV+ NHL patients were studied. CD4 and CD8 cell counts, HHV8 DNA, EBV DNA, HIV RNA and HIV DNA were assessed at diagnosis and at 3 months after chemotherapy initiation. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) of disease free survival (DFS) and overall survival (OS) were computed according to CD4 and CD8 cell counts, EBV DNA, HIV RNA and HIV DNA. HRs were, thereafter, computed also for continuous variation of CD4, CD8 cell counts and EBV DNA. Results: In the multivariate analysis, CD4 <160 and CD8 <590. cell/μl and EBV DNA ≥ 300. c/ml were independently associated to DFS (HR = 2.98; 95%CI: 1.26-7.03; HR = 2.65, 95%CI: 1.13-6.19; HR = 4.01; 95%CI: 1.81-8.91) and OS (HR = 3.32; 95%CI: 1.41-7.83; HR = 4.62, 95%CI: 1.91-11.19; HR = 3.11, 95%CI: 1.42-6.80). HRs for DFS and OS decreased continuously with increasing CD4 and CD8 cell counts, while they increased continuously with increasing EBV DNA levels. Conclusions: The association with survival of low CD4 and CD8 cell counts and detectable EBV viremia, measured at lymphoma's diagnosis, identified three independent prognostic biomarkers that might help in the management of NHL HIV+ patients, offering complementary information in the ascertainment of their outcome.
AB - Background: Despite the era of highly active antiretroviral therapy, non-Hodgkin lymphoma (NHL) remains one of the main causes of death in HIV-infected patients, with a wide variation on the outcome. Objectives: We investigated immunological status and EBV, HHV8, HIV viral load in a group of HIV-infected patients at diagnosis of NHL to evaluate their prognostic significance. Study design: Eighty-one consecutive HIV+ NHL patients were studied. CD4 and CD8 cell counts, HHV8 DNA, EBV DNA, HIV RNA and HIV DNA were assessed at diagnosis and at 3 months after chemotherapy initiation. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) of disease free survival (DFS) and overall survival (OS) were computed according to CD4 and CD8 cell counts, EBV DNA, HIV RNA and HIV DNA. HRs were, thereafter, computed also for continuous variation of CD4, CD8 cell counts and EBV DNA. Results: In the multivariate analysis, CD4 <160 and CD8 <590. cell/μl and EBV DNA ≥ 300. c/ml were independently associated to DFS (HR = 2.98; 95%CI: 1.26-7.03; HR = 2.65, 95%CI: 1.13-6.19; HR = 4.01; 95%CI: 1.81-8.91) and OS (HR = 3.32; 95%CI: 1.41-7.83; HR = 4.62, 95%CI: 1.91-11.19; HR = 3.11, 95%CI: 1.42-6.80). HRs for DFS and OS decreased continuously with increasing CD4 and CD8 cell counts, while they increased continuously with increasing EBV DNA levels. Conclusions: The association with survival of low CD4 and CD8 cell counts and detectable EBV viremia, measured at lymphoma's diagnosis, identified three independent prognostic biomarkers that might help in the management of NHL HIV+ patients, offering complementary information in the ascertainment of their outcome.
KW - CD4
KW - CD8
KW - EBV
KW - HIV
KW - NHL
KW - Viral load
UR - http://www.scopus.com/inward/record.url?scp=84858151900&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858151900&partnerID=8YFLogxK
U2 - 10.1016/j.jcv.2011.12.021
DO - 10.1016/j.jcv.2011.12.021
M3 - Article
C2 - 22244256
AN - SCOPUS:84858151900
VL - 53
SP - 297
EP - 301
JO - Journal of Clinical Virology
JF - Journal of Clinical Virology
SN - 1386-6532
IS - 4
ER -